Unicycive Therapeutics (UNCY) Stock Forecast & Price Target

Unicycive Therapeutics is attractive because the core FDA hurdle for OLC now appears largely procedural rather than clinical, with regulators citing manufacturing deficiencies only, no concerns about efficacy or safety, and a new vendor that already produced product to specification, completed 12-month stability studies, and earned a March 2024 NAI inspection outcome. The company’s financial position also supports the thesis, as $61.4M in cash and equivalents and no immediate need for dilution appear sufficient to fund operations into 2027, while the simplified 27.9M share count and completed preferred conversion reduce capital structure complexity. If approval follows the inspection and resubmission path, TDAPA could lift OLC into a highly favorable reimbursement window, with projected risk-adjusted U.S. net sales reaching roughly $400M in 2028E and a broader commercial opportunity that extends beyond the ESRD bundle.

Unicycive Therapeutics is viewed negatively because its value depends heavily on a single lead asset, OLC, that still faces binary FDA, manufacturing, and labeling risks, with approval now expected only at the end of 1Q27 and sales not beginning until 2Q27. The company also has a long history of operating losses, no product revenue, and limited liquidity of $61.4M at 2Q26, while management expects cash to fund operations only into 2H27 and the company may need additional capital that could dilute shareholders through warrant conversions or future financing. Even if approved, revenue assumptions have been reduced to $27.5M for FY2027 and commercialization remains vulnerable to slow dialysis contracting, reimbursement uncertainty under the ESRD PPS and TDAPA framework, and competition from existing phosphate binders.